Moneycontrol
SENSEX NIFTY
DIL > Company History > Pharmaceuticals > Company History of DIL - BSE: 506414, NSE: N.A
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > COMPANY BACKGROUND - DIL

DIL

BSE: 506414|ISIN: INE225B01013|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Apr 27, 12:24
741.00
-33 (-4.26%)
VOLUME 5
DIL is not listed on NSE
Array
Company History - DIL
YEAR                       EVENTS
 1951 - The company was Incorporated on 1st May, as a private limited
        company under the name International Franchise Pvt.  The
 Company
        manufacture drugs and pharmaceuticals, chemicals, cosmetics
 and
        toileteries.  It started its activities with the manufacture
 of a
        brand of tooth paste and antiseptic lotion and extended them
 to
        the manufacture of pharmaceutical specialities of foreign
        companies on leave licence scheme.
 
      - DIL was promoted by Solvay Pharmaceuticals based Brussels and
        Mr. D. Vasant Kumar and family in India.
 
 1962 - The Collaboration agreements were concluded with N.V. Philips
 -
        Duphar of Amsterdam and the Crookes Laboratories Ltd., London.
 
        The Company became a public limited company with effect from
 9th
        April, 1963 and simultaneously its name was changed to
 Crookes
        Interfran Ltd.
 
      - The Company was entitled to obtain technical know-how for the
        manufacture of basic chemical, Vitamin `D' from N.V. Philips
        `Gloeilampenfabrieken, Holland.
 
 1967 - The first phase of vitamin `D' manufacture was undertaken in
 May
        from imported resin.  Import substitution was implemented in
        certain chemicals like neo-ferrum flakes, iodine concentrate
 and
        paracetamol.
 
      - 800 No. of equity share and 200 pref. shares issued by Feb.
 1963.
        Around March 1963, 800 No. of equity shares issued at par to
        collaborators.  Around Dec. 1964, 800 right equity shares
 issued
        at par in prop. 1:2 and pref. shares redeemed.  In Sept.
 1967,
        1,200 No. of equity shares issued at par in prop. 1:2.  In
 Sept.
        1969, Rs 9 lakhs capitalised to make partly paid shares fully
        paid-up.
 
 1971 - The name of the Company was changed to Duphar-Interfran Ltd.
 
 1975 - The second phase was (irradiation) of vitamin `D' was
        implemented.  The Company's products included `Crookes'
        transfusion, crocin and lacto-calamine, Duphar's research
        specialities of vasodilators and progrestational agents.
 
      - In Dec. 1970, shares subdivided.  In Oct. 1975, 36,000 bonus
        shares issued in prop. 1:1.
 
 1977 - On 24-12-1976, shares subdivided.  During July 1977, 2,00,000
        shares offered (prem. Rs 2.50 per share) to the public.
 
 1979 - The Company undertook to set up a joint venture company under
 the
        name Fermentapharma Biodil Ltd., at Takoli village, Mandi
        district in Himachal Pradesh for the manufacture of basic
 drug
        intermediates used in the production of essential
 semi-synthetic
        antibiotics.
 
 1984 - A modernisation and replacement to programme was taken up at
 the
        cost of Rs 100 lakhs.
 
      - 4,60,000 bonus equity shares issued in prop. 1:2.
 
 1985 - Profitability was affected by a strike in the Vapi unit.  The
        Vapi factory could not make adequate contribution to sales on
        account of low employee effectiveness.
 
      - The Company obtained registration for the manufacture of some
        bulk drugs and their formulations.
 
 1988 - The Company privately placed with financial institutions
        1,20,000-14% non-convertible debentures of Rs 100 each for Rs
 120
        lakhs.
 
      - 4,60,000 bonus shares issued in prop. 1:3.
 
 1991 - 3,22,000 shares issued (prem. Rs 35 per share), 3.06,667
 shares
        rights (prop. 1:6) and 15,333 shares to employees (all were
 taken
        up).  Allotment was made on 1.6.1991.
 
 1992 - The Company continued to concentrate towards development of
 new
        formulation, bulk drugs and intermediates in the field of
        synthetic and fermentation technology and in improving
 process
        of the existing formulation and bulk drugs.
 
      - The Company proposed to set up a third manufacturing unit at
        Takwe, Maharashtra for the commercial production of
 formulation.
        The company proposed to introduce Vitamin D3 combination for
        veterinary use.
 
      - The Company has developed chemical preparation of Sulbactam,
 a
        beta-lactamase inhibitor.  Amoxycillin Dispersible Tablet was
        introduced in the market.
 
      - During the year the company's Pilot Plant was engaged in the
        scaling up of in-house processes developed by the company's R
 & D
        Division for the manufacture of 7-ADCA by enzymatic conversion
 of
        Ceph-G, jCephalexin and Sulbactam. Besides , locally
 developed
        technology for Cholorzoxazone was tried out in the Pilot
 Plant.
 
      - It is proposed to install Heat Recovery System and a high
        efficiency boiler at the Vapi Works.
 
 1993 - The Company has undertaken expansion programme by recreating
 its
        Vitamin D3 plant at Thane.
 
      - Vitamin D3 preparation in Arachis Oil for Animal Feed was
        developed.  The Company proposes to introduce Vitamin D3
        combination for veterinary use.
 
      - During the year the company's Pilot Plant was engaged in the 
        scaling up of in-house processes for Sulbactam and
 Chlorzoxazone.  
 
 1994 - The Company, proposed to issue 3,60,333 New Equity Shares of
 Rs.
        10/- each as Rights Shares at a premium of Rs.45 per share.
 These
        shares will be offered to the Shareholders of the Company in
 the
        ratio of one such New Equity Share for every six existing
 shares
        held.
 
      - Two new bulk drugs namely Chlorzoxazone and Sulbactam Sodium
        which were developed through indigenously developed in-house
        technology have been successfully manufactured on commercial
        scale essentially for captive consumption.
 
      - Vitamin D3, liquid formulation for Animal Feed has been
 developed
        and is being launched in the market.
 
 1995 - The Company offered 3,60,333 No. of equity shares of Rs 10
 each
        at a premium of Rs 45 per share on rights basis to the
 existing
        shareholders in the ratio of 1:6.  The number of shares
 offered
        was increased to 3,62,871 on account of rounding off of
        fractional entitlement.  All were taken up.
 
      - The Company set up a third manufacturing unit at village
 Takwe
        (Budruk), Taluka - Maval, District - Pune.
 
 1996 - The Company effected sale of its main product namely, Crocin
        range during the year since it was not giving the expected
        growth and yield and its contribution to profit was at a
        decreasing rate.
 
      - The Company has already launched in February one of the
 Gynaec
        products under the brand name Yutopar.  The other new
 products
        in the pipeline are Luvox, a psychotropic product.
 
      - The Company introduced Voluntary Retirement Scheme for its
        workmen and staff members at Thane Factory and Head Office.
 
 1997 - During the year, the Company launched a new product under the
        brand name UDILIV for chronic hepatitis, cholestasis and
        dissolution of gall stones indications.
 
      - The Company has an R & D Laboratory approved by DSIR for
        chemicals and pharmaceutical research and development
 activity. 
 
      - A wage settlement was signed with Unions of Medical
        Representatives.  Similarly, a wage agreement with the Union
 of
        Thane and H.O. Workmen and Staff was also signed.
 
 1998 - Duphar-Interfran is present in categories like antibiotics,
        anti-stress therapy, iodine therapy and muscle spasm.  Some
 of
        its well-known brands include Moxydil, Ginsec and Duodil
        tablets.
 
      - Duphar is also planning to launch new formulations in various
        categories.
 
      - The company's R&D laboratory is now trying to develop and
        market new animal-feed supplement containing vitamins and
        minerals.
 
      - Duphar-Interfran also plans to launch formulations in various
        categories.  The company launched a product under the brand
 name
        Udiliv for chronic hepatitis, cholestasis and dissolution of
 gall
        stones indications.
 
 1999 - The Company has DSIR approved R&D Centre.  During the year,
        research programme for finding out new lead molecules of
        medicinal importance and development of indigenous
 technologies
        for major drugs and intermediates were continued.
 
      - Electrical capacitors of sufficient size were installed at
 main
        electrical distribution and at key motor control panels by
 which
        the power factor was maintained at the efficient level
 resulting
        in considerable power saving.
 
      - The Company has an extensive computer network.
 
 2000 - Duphar-Interfran Ltd (DIL) has said it is demerging its
        pharmaceutical business into a new company.
 
      - The Company has signed agreements with NSDL and CDSL for
        dematerialisation of the company's shares and for electronic
        connectivity.
 
 2002-Duphar-Interfran Ltd has informed that Mr Kunal Kashyap has been
 appointed as a Director on the Board of the company.
 
 2005
 -Registered Office of the Company has been shifted  From Worli,
 Mumbai to Thane
 
 2007
 
 - Dil Ltd has appointed Mr. Sanjay Buch as an additional director
 (Independent Category) with effect from April 28, 2007.
 
 2008
 
 -Dil Ltd has recommended an equity dividend of 100%
 
 2009
 
 -Dil Ltd has declared Interim Dividend & recommended Final Dividend
 of Rs 7.50 per share respectively.
 
 2010
 
 -Dil Ltd has recommended final equity dividend @ Rs. 7.50/- per
 equity share
 
 -Dil Ltd has declared Interim Dividend @ Rs. 7.50/- per equity share
 
 2011
 
 -Dil Ltd has recommended final equity dividend @ Rs. 10/- per equity
 share 
 
 -Dil Ltd has declared interim equity dividend @ Rs. 15/- per equity
 share 
 
 2012
 
 -Dil Ltd has recommended final equity dividend @ Rs. 15/- per equity
 share
 
 -Dil Ltd has declared interim equity dividend @ Rs. 15/- per equity
 share 
 
 2013
 
 -Dil Ltd has signed Agreement with Advertising Agents and
 Consultants.
 
 2014
 
 -Board has been appointed Dr. Gopakumar Nair as an Additional
 Director of the company.
 
 
Source :
Quick Links for DIL
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.